208 related articles for article (PubMed ID: 23530772)
1. Characterization and application of a nose-only exposure chamber for inhalation delivery of liposomal drugs and nucleic acids to mice.
Mainelis G; Seshadri S; Garbuzenko OB; Han T; Wang Z; Minko T
J Aerosol Med Pulm Drug Deliv; 2013 Dec; 26(6):345-54. PubMed ID: 23530772
[TBL] [Abstract][Full Text] [Related]
2. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug.
Garbuzenko OB; Saad M; Betigeri S; Zhang M; Vetcher AA; Soldatenkov VA; Reimer DC; Pozharov VP; Minko T
Pharm Res; 2009 Feb; 26(2):382-94. PubMed ID: 18958402
[TBL] [Abstract][Full Text] [Related]
3. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
[TBL] [Abstract][Full Text] [Related]
4. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA.
Taratula O; Kuzmov A; Shah M; Garbuzenko OB; Minko T
J Control Release; 2013 Nov; 171(3):349-57. PubMed ID: 23648833
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system.
Pakunlu RI; Wang Y; Tsao W; Pozharov V; Cook TJ; Minko T
Cancer Res; 2004 Sep; 64(17):6214-24. PubMed ID: 15342407
[TBL] [Abstract][Full Text] [Related]
6. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA.
Taratula O; Garbuzenko OB; Chen AM; Minko T
J Drug Target; 2011 Dec; 19(10):900-14. PubMed ID: 21981718
[TBL] [Abstract][Full Text] [Related]
7. Preclinical study of Doxorubicine-loaded liposomal drug delivery for the treatment of head and neck cancer: Optimization by Box-Behnken statistical design.
Yang B
Acta Biochim Pol; 2020 Jun; 67(2):149-155. PubMed ID: 32506868
[TBL] [Abstract][Full Text] [Related]
8. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of CPP decorated doxorubicin and CPP decorated siRNA by NGR-modified nanobubbles for improving anticancer therapy.
Ma R; Nai J; Zhang J; Li Z; Xu F; Gao C
Pharm Dev Technol; 2021 Jul; 26(6):634-646. PubMed ID: 33843423
[TBL] [Abstract][Full Text] [Related]
10. Targeted delivery of transferrin-conjugated liposomes to an orthotopic model of lung cancer in nude rats.
Gaspar MM; Radomska A; Gobbo OL; Bakowsky U; Radomski MW; Ehrhardt C
J Aerosol Med Pulm Drug Deliv; 2012 Dec; 25(6):310-8. PubMed ID: 22857016
[TBL] [Abstract][Full Text] [Related]
11. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.
Yin X; Feng S; Chi Y; Liu J; Sun K; Guo C; Wu Z
Drug Deliv; 2018 Nov; 25(1):900-908. PubMed ID: 29644882
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance.
Garbuzenko OB; Saad M; Pozharov VP; Reuhl KR; Mainelis G; Minko T
Proc Natl Acad Sci U S A; 2010 Jun; 107(23):10737-42. PubMed ID: 20498076
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy.
Chen Y; Wu JJ; Huang L
Mol Ther; 2010 Apr; 18(4):828-34. PubMed ID: 20068551
[TBL] [Abstract][Full Text] [Related]
14. Robust, tumor-homing and redox-sensitive polymersomal doxorubicin: A superior alternative to Doxil and Caelyx?
Zou Y; Meng F; Deng C; Zhong Z
J Control Release; 2016 Oct; 239():149-58. PubMed ID: 27569664
[TBL] [Abstract][Full Text] [Related]
15. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer.
Saad M; Garbuzenko OB; Minko T
Nanomedicine (Lond); 2008 Dec; 3(6):761-76. PubMed ID: 19025451
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug.
Pakunlu RI; Wang Y; Saad M; Khandare JJ; Starovoytov V; Minko T
J Control Release; 2006 Aug; 114(2):153-62. PubMed ID: 16889867
[TBL] [Abstract][Full Text] [Related]
17. A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy.
Paliwal SR; Paliwal R; Mishra N; Mehta A; Vyas SP
Curr Cancer Drug Targets; 2010 May; 10(3):343-53. PubMed ID: 20370682
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of folate-targeted liposomal doxorubicin in KB tumor-bearing mice after intravenous administration.
Riviere K; Huang Z; Jerger K; Macaraeg N; Szoka FC
J Drug Target; 2011 Jan; 19(1):14-24. PubMed ID: 20353291
[TBL] [Abstract][Full Text] [Related]
19. The suppression of metastatic lung cancer by pulmonary administration of polymer nanoparticles for co-delivery of doxorubicin and Survivin siRNA.
Xu C; Tian H; Wang P; Wang Y; Chen X
Biomater Sci; 2016 Oct; 4(11):1646-1654. PubMed ID: 27709139
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary Codelivery of Doxorubicin and siRNA by pH-Sensitive Nanoparticles for Therapy of Metastatic Lung Cancer.
Xu C; Wang P; Zhang J; Tian H; Park K; Chen X
Small; 2015 Sep; 11(34):4321-33. PubMed ID: 26136261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
